185 related articles for article (PubMed ID: 32991919)
1. Polypharmacy and mobility outcomes.
Ali MU; Sherifali D; Fitzpatrick-Lewis D; Kenny M; Liu A; Lamarche L; Mangin D; Raina P
Mech Ageing Dev; 2020 Dec; 192():111356. PubMed ID: 32991919
[TBL] [Abstract][Full Text] [Related]
2. Thoughtful Prescribing and Deprescribing.
Pravodelov V
Med Clin North Am; 2020 Sep; 104(5):751-765. PubMed ID: 32773043
[TBL] [Abstract][Full Text] [Related]
3. The value of deprescribing in older adults with dementia: a narrative review.
Sawan MJ; Moga DC; Ma MJ; Ng JC; Johnell K; Gnjidic D
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1367-1382. PubMed ID: 34311630
[No Abstract] [Full Text] [Related]
4. Optimising pharmacotherapy in older cancer patients with polypharmacy.
Vrijkorte E; de Vries J; Schaafsma R; Wymenga M; Oude Munnink T
Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13185. PubMed ID: 31692151
[TBL] [Abstract][Full Text] [Related]
5. CE: Mitigating the Dangers of Polypharmacy in Community-Dwelling Older Adults.
Gabauer J
Am J Nurs; 2020 Feb; 120(2):36-42. PubMed ID: 31977416
[TBL] [Abstract][Full Text] [Related]
6. GPs' management of polypharmacy and therapeutic dilemma in patients with multimorbidity: a cross-sectional survey of GPs in France.
Carrier H; Zaytseva A; Bocquier A; Villani P; Verdoux H; Fortin M; Verger P
Br J Gen Pract; 2019 Apr; 69(681):e270-e278. PubMed ID: 30803978
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacy: Evaluating Risks and Deprescribing.
Halli-Tierney AD; Scarbrough C; Carroll D
Am Fam Physician; 2019 Jul; 100(1):32-38. PubMed ID: 31259501
[TBL] [Abstract][Full Text] [Related]
8. The Role of Deprescribing in Older Adults with Chronic Kidney Disease.
Triantafylidis LK; Hawley CE; Perry LP; Paik JM
Drugs Aging; 2018 Nov; 35(11):973-984. PubMed ID: 30284120
[TBL] [Abstract][Full Text] [Related]
9. How "age-friendly" are deprescribing interventions? A scoping review of deprescribing trials.
Wang J; Shen JY; Conwell Y; Podsiadly EJ; Caprio TV; Nathan K; Yu F; Ramsdale EE; Fick DM; Mixon AS; Simmons SF
Health Serv Res; 2023 Feb; 58 Suppl 1():123-138. PubMed ID: 36221154
[TBL] [Abstract][Full Text] [Related]
10. Inappropriate polypharmacy management versus deprescribing: A review on their relationship.
Zidan A; Awaisu A
Basic Clin Pharmacol Toxicol; 2024 Jan; 134(1):6-14. PubMed ID: 37350370
[TBL] [Abstract][Full Text] [Related]
11. Combating Polypharmacy Through Deprescribing Potentially Inappropriate Medications.
Chou J; Tong M; Brandt NJ
J Gerontol Nurs; 2019 Jan; 45(1):9-15. PubMed ID: 30653232
[TBL] [Abstract][Full Text] [Related]
12. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.
Page AT; Clifford RM; Potter K; Schwartz D; Etherton-Beer CD
Br J Clin Pharmacol; 2016 Sep; 82(3):583-623. PubMed ID: 27077231
[TBL] [Abstract][Full Text] [Related]
13. Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review.
Aubert CE; Kerr EA; Maratt JK; Klamerus ML; Hofer TP
J Am Geriatr Soc; 2020 Oct; 68(10):2390-2398. PubMed ID: 32780416
[TBL] [Abstract][Full Text] [Related]
14. Polypharmacy, the Elderly, and Deprescribing.
Jetha S
Consult Pharm; 2015 Sep; 30(9):527-32. PubMed ID: 26350893
[TBL] [Abstract][Full Text] [Related]
15. Continue or not to continue? Attitudes towards deprescribing among community-dwelling older adults in China.
Tan J; Wang M; Pei X; Sun Q; Lu C; Wang Y; Zhang L; Wu C
BMC Geriatr; 2022 Jun; 22(1):492. PubMed ID: 35676628
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens.
Rochon PA; Petrovic M; Cherubini A; Onder G; O'Mahony D; Sternberg SA; Stall NM; Gurwitz JH
Lancet Healthy Longev; 2021 May; 2(5):e290-e300. PubMed ID: 36098136
[TBL] [Abstract][Full Text] [Related]
17. Deprescribing: a new goal focused on the patient.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME; Chica L
Expert Opin Drug Saf; 2017 Feb; 16(2):111-112. PubMed ID: 27984921
[TBL] [Abstract][Full Text] [Related]
18. Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland.
Zechmann S; Trueb C; Valeri F; Streit S; Senn O; Neuner-Jehle S
BMC Fam Pract; 2019 May; 20(1):64. PubMed ID: 31088397
[TBL] [Abstract][Full Text] [Related]
19. Development and dissemination of the national strategic action plan for reducing inappropriate polypharmacy in older Australians.
Kouladjian O'Donnell L; Reeve E; Cumming A; Scott IA; Hilmer SN
Intern Med J; 2021 Jan; 51(1):111-115. PubMed ID: 33572018
[TBL] [Abstract][Full Text] [Related]
20. Deprescribing in multi-morbid older people with polypharmacy: agreement between STOPPFrail explicit criteria and gold standard deprescribing using 100 standardized clinical cases.
Curtin D; Dukelow T; James K; O'Donnell D; O'Mahony D; Gallagher P
Eur J Clin Pharmacol; 2019 Mar; 75(3):427-432. PubMed ID: 30421220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
